Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pimavanserin

            Therapeutic Area: Psychiatry/Psychology Product Name: Nuplazid

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2021


            The OLE study was designed to evaluate the long-term safety of NUPLAZID. All patients in the OLE were treated with NUPLAZID 34 mg. Of 459 patients enrolled in the OLE, 424 (92.4%) had a Week 4 efficacy assessment.